Diverse and distinct subtypes of HIV-1, including complex circulating recombinant forms (CRFs), have been outstripping the prototypic subtype B isolates in much of Africa, Latin America, and Asia. However, in the course of drug development, preclinical in vitro studies, pivotal clinical trials, and analyasis of long-term treatment have largely focused on subtype B virus infection. With "scale-up" in global treatment, the pathogenesis and drug susceptibility of non-subtype B HIV-1 infection outside of the United States is a critical question for regional and national treatment guidelines and for clinicians in the United States and Europe who are confronting an increasingly cosmopolitan epidemic.
The work of Kinomoto, AppiahOpong, and colleagues [1] Analysis of these clinical trials may provide insight into the effects of variation in viral subtype and host genomics. However, among the widely divergent and evolving subtypes and CRFs, even large international trials are powered to address only very dramatic differences among subtypes in the efficacy of drugs and drug combinations.
Consistent differences between subtypes are the result of founder effects and immunologic pressure caused by distinct HLA alleles [2] . Differences in the drug susceptibility of non-subtype B viruses rely largely on genotypic analyses of gagpol sequences and characterizations of the effects of subtype-specific mutations associated with drug resistance in subtype B. Fortunately, the pace of virologic analysis has quickened with increasing international access to drug treatment and resistance testing. Reviewing recent publications through a search of the National Institute of Health's PubMed database reveals that investigators from Brazil, India, Malaysia, Israel, South Africa, and North America have probed differences in protease inhibitor-associated polymorphisms and gag cleavage site mutations in non-B subtypes. They have described emerging recombinant viruses and have explored relative fitness, distinct codon usage, and selection of specific resistance pathways in certain non-B subtypes [3] [4] [5] [6] [7] [8] [9] . However, phenotypic studies of non-subtype B isolates obtained from untreated subjects are still very limited. An understanding of the phenotypic consequences of subtype-specific mutations is important to identify future drug options for individual patients and the initial and sequential drugs for regional treatment guidelines.
Epidemiologic studies of drug resistance among HIV-1 subtypes have largely focused on gag-pol gene mutations that depend on bioinformatics to digest and analyze large sequence and protein databases. Kinomoto et al. [1] note in their discussion that "we may, therefore, need the establishment of a non-subtype Bbased resistance database for more insights into the role of those mutations" [1, p. 249] . At Stanford University, with the collaboration of 28 international virologists, Rami Kantor has analyzed sequence data from 3686 persons in 56 countries infected with non-B HIV-1 subtypes [10] . This broad look at non-B subtypes and the relationship of treatment to protease polymorphisms identified many of the same sites found in the present CRF02_AG isolates from Ghana investigated by Kinomoto et al. [1] . However, the contribution of individual protease mutations to low-level drug resistance and the importance of these mutations for phenotypic resistance and treatment response will require more intensive work.
Definitive studies to investigate the significance of inter-and intrasubtype differences in polymorphisms to resistance to specific drugs in vitro require sensitive and accurate recombinant phenotypic assays. In most phenotypic assays, gag-pol genes from the test virus (or, preferably, from a sequenced clone) are inserted into a subtype B backbone, and the susceptibility to drugs is assessed by measuring virus replication in the presence of drugs. The current study used just such a strategy, although without comparison to diverse clinical isolates or a range of wild-type gagpol genes from subtype B. Additionally, in the evaluation of protease inhibitors, there are arguments for the inclusion of native gag protein in the recombinant virus or substrate(s) to identify the selection of cleavage site mutations. Similar arguments can be made for env (and, ultimately, for a whole virus assay), because protease also plays an important processing role in other HIV-1 gene products.
Kinomoto et al. [1] performed sophisticated molecular modeling of structurefunction relationships to calculate inhibitor-ligand binding interactions, comparing different enzymes and inhibitors that may require some qualifications. One limitation of the analysis is that the attempt to ascribe the significant difference in inhibition constants to structural differences may need more careful structural analysis of proteinligand complexes. It is challenging to gain an understanding of the structure/activity relationships at play with even closely related drug structures and/or protein polymorphs. A second limitation is the differences between calculated structures and interactions and those determined empirically by inhibitor-enzyme crystal structures. Minimization routines to calculated ligand binding (including those presented in Kinomoto et al. [1] ) are conducted, of necessity, with predetermined constraints placed on certain atoms to limit computing time. However, crystallographers have documented significant changes in protein side-chain packing with mutant structures and different inhibitors. The minimization and docking procedures suggest that a conformational change in the ligand may be the source of the difference in binding between subtypes B and CRF02_ AG proteases with certain protease inhibitors. In many structures of HIV protease bound with relatively inflexible inhibitors, it is the side chains of the protein and occasionally the backbone that show movement [11] . Subtle differences in binding may contrast with the huge movements of the "flaps" of protease associated with drug binding as drug and protease are varied. Modeling techniques have been applied to the question of flap movements associated with drug and substrate binding [12] . The modeling presented in Kinomoto et al. [1] shows only subtle differences in binding. Whether the calculated differences in "insertability" of an inhibitor into a mutant structure can account for small differences in the activity of a drug is an intriguing question, but one that is still highly speculative.
Will the results of these studies influence decisions about protease inhibitor therapies in West Africa or in patients infected with subtype CRF02_AG viruses? To a great extent, the guidelines for antiretroviral therapy have already incorporated the recommendation for pharmacologic boosting of protease inhibitors with ritonavor to avoid selecting resistance through subinhibitory drug levels. The ordering of binding coefficients, phenotypic susceptibility, and a predicted genotypic susceptibility to current protease inhibitors for HIV-1 subtype CRF02_AG are important. Combined with drug tolerability, regimen pill burden, cost, and pharmacologic properties, relative drug activity will play a role in optimizing effective regimens to meet the complex challenge of the need for effective HIV treatment in Africa. This is a thoughtful investigation of the mechanism of drug resistance as we enter an era of increasing treatment programs worldwide.
